Results 91 to 100 of about 950,946 (355)

Advax, a Delta Inulin Microparticle, Potentiates In-built Adjuvant Property of Co-administered Vaccines

EBioMedicine, 2017
Advax, a delta inulin-derived microparticle, has been developed as an adjuvant for several vaccines. However, its immunological characteristics and potential mechanism of action are yet to be elucidated.
Masayuki Hayashi, Taiki Aoshi, Yasunari Haseda, Kouji Kobiyama, Edward Wijaya, Noriyuki Nakatsu, Yoshinobu Igarashi, Daron M. Standley, Hiroshi Yamada, Yoshikazu Honda-Okubo, Hiromitsu Hara, Takashi Saito, Toshiyuki Takai, Cevayir Coban, Nikolai Petrovsky, Ken J. Ishii   +15 more
doaj   +1 more source

Tumor markers in breast cancer - European Group on Tumor Markers recommendations [PDF]

, 2005
Recommendations are presented for the routine clinical use of serum and tissue-based markers in the diagnosis and management of patients with breast cancer.
Abraha RS, Andreasen PA, Arie van Dalen, ASCO Expert Panel, Barak V, Barnes DM, Baselga J, Bast RC, Benraad TH, Bieglmayer C, Blamey RW, Bonadonna G, Chan DW, Chebil G, Chu KC, Colditz G, Conneely OM, De Koning H, Devine PL, Dixon AR, Dnistrian AM, Dnistrian AM, Duffy MJ, Duffy MJ, Duffy MJ, Duffy MJ, Duffy MJ, Early Breast Cancer Trialist's, Early Breast Cancer Trialists Collaborative Group, Early Breast Cancer Trialists Collaborative Group, Easton DF, Ebeling FC, Ebeling FG, Eifel P, Einarsson R, Ekbom A, Elledge RM, Fisher B, Fitzgibbons PL, Gion M, Gion M, Guadagni F, Gyö, Harries M, Harvey JM, Helena Goike, Holli K, Holli K, Iwase H, Jager W, Jensen EV, Kamel EM, Konecny G, Kurebayashi J, Lamerz R, Leake R, Leers M, Leers MP, Leers MP, Legha SS, Leyland-Jones B, Look MP, Loomer L, Loprinzi CL, Madigan MP, Marius Nap, Massimo Gion, McCarty, McLaughlin R, Merimsky O, Michael J. Duffy, Mohsin SK, Molina R, Molina R, Molina R, Molina R, Molina R, Molina R, Molina R, Morrow M, Nakata B, Newcomb P, Nicolini A, Nicolini A, Nicolini A, O'Hanlon DM, Paik S, Palazzo S, Parker SL, Parkin DN, Pecking AP, Pertschuk LP, Pertschuk LP, Petra Stieber, Piccart MJ, Price MR, Rafael Molina, Robertson JFR, Robertson JFR, Rogers CE, Roland Einarsson, Rolf Lamerz, Romer M, Rosselli del Turco M, Safi F, Schapira DV, Schapira DV, Sjostrom J, Slamon D, Soletormos G, Soletormos G, Soletormos G, Soletormos G, Stieber P, Sturgeon CM, Sweep CGJ, Tabar L, The GIVIO, The GIVIO, Theriault RL, Thorpe SM, Tomlinson IP, Tondini C, Van Dalen A, Van Dalen A, van Dalen A, van Dalen A, Van Dalen A, van Dalen A, Veronesi U, Vivian Barak, Vizcarra E, Vyzula R, Weihua Z, Williams MR, Yamauchi H, Zucchelli GC   +136 more
core   +1 more source

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

PB2114: TREATMENT RESULTS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA FROM HIGH-RISK GROUP

HemaSphere, 2022
K. Filonenko, I. Kriachok, A. Martynchyk, I. Titorenko, Y. Stepanishyna, O. Aleksyk, K. Ukianchenko, I. Pastushenko, Y. Kushchevyy, O. Novosad, O. Karnabeda, I. Diagil, V. Kozlov   +12 more
doaj   +1 more source

Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5 [PDF]

, 2017
Background The purpose of this study was to determine the cardiac safety and clinical activity of trastuzumab and bevacizumab with docetaxel after epirubicin with cyclophosphamide (EC) in patients with HER2-positive locally advanced breast cancer (LABC ...
Ansari, Bilal, Buyse, Marc E., Conlin, Alison K., Geyer, Charles E., Jr., Gross, Howard M., Jacobs, Samuel A., Keogh, George P., Lord, Raymond S., Mamounas, Eleftherios P., Mauquoi, Celine, Patocskai, Erica J., Polikoff, Jonathan A., Rastogi, Priya, Robidoux, André, Smith, John W., Stella, Philip J., Swain, Sandra M., Wolmark, Norman   +17 more
core   +2 more sources

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

Molecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena, Karin Teien Lande, Eva Diaz, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Alicia Abalo, Nerea González, Eva Colás, Antonio Gil‐Moreno, Miguel Abal, Gema Moreno‐Bueno, Therese Sørlie, Kristina Lindemann, Laura Muinelo‐Romay   +15 more
wiley   +1 more source

Host- and Microbe-Dependent Dietary Lipid Metabolism in the Control of Allergy, Inflammation, and Immunity

Frontiers in Nutrition, 2019
The intestine is the largest immune organ in the body, provides the first line of defense against pathogens, and prevents excessive immune reactions to harmless or beneficial non-self-materials, such as food and intestinal bacteria.
Azusa Saika, Azusa Saika, Takahiro Nagatake, Jun Kunisawa, Jun Kunisawa, Jun Kunisawa, Jun Kunisawa, Jun Kunisawa   +7 more
doaj   +1 more source

Identification of subgroups of early breast cancer patients at high risk of nonadherence to adjuvant hormone therapy: results of an italian survey. [PDF]

, 2015
The aim of this study was the identification of subgroups of patients at higher risk of nonadherence to adjuvant hormone therapy for breast cancer. Using recursive partitioning and amalgamation (RECPAM) analysis, the highest risk was observed in the ...
Cianchetti E, Fabbri MA, Fanizza C, Fattoruso SI, Gambale E, Gamucci T, Gori S, Grassadonia A, Laudadio L, Longo F, Mauri M, Mazzilli L, Moscetti L, Natoli C., Nuzzo A, Romero M, SEMINARA, Patrizia, Tinari N, Vaccaro A, Vici P   +19 more
core   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source